Drugs / P-MUC1C-ALLO1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05239143 | Feb 2022 → Apr 2026 overdue | breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +5 | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-MUC1C-ALLO1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05239143 ↗ |
| Modality | Cell therapy | “P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen.” NCT05239143 ↗ |
| Route | Intravenous | “given in a single intravenous infusion of CAR-T cells” NCT05239143 ↗ |
| Target | MUC1 | “P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen.” NCT05239143 ↗ |